smpd4 Antibody

What is SMPD4 and why is it significant for neurodevelopmental research?

SMPD4 encodes a sphingomyelinase that hydrolyses sphingomyelin into ceramide at neutral pH, affecting membrane lipid homeostasis. This enzyme is particularly significant because biallelic loss-of-function variants cause a rare and severe neurodevelopmental disorder characterized by progressive congenital microcephaly . Additionally, individuals with SMPD4-related disorders who survive beyond infancy frequently develop insulin-dependent diabetes, making it an important target for both neurological and metabolic research . SMPD4 localizes to the endoplasmic reticulum and nuclear envelope membranes and interacts with nuclear pore complexes (NPCs), suggesting its involvement in critical cellular processes .

What cellular structures and processes can be studied using SMPD4 antibodies?

SMPD4 antibodies enable research into several critical cellular structures and processes:

• Nuclear envelope dynamics: SMPD4 depletion results in abnormal nuclear envelope breakdown and reassembly during mitosis .

• Nuclear pore complex insertion: Post-mitotic NPC insertion is decreased in SMPD4-depleted cells .

• Primary cilia development and function: Mouse and human stem cell models show SMPD4 promotes cilia function, which is crucial for neural development .

• Neural progenitor proliferation: SMPD4 knockdown impairs cortical progenitor proliferation and alters the balance between neurogenic and proliferative divisions .

• Sphingolipid metabolism: SMPD4 links homeostasis of membrane sphingolipids to cell fate by regulating cross-talk between the ER and outer nuclear envelope .

What are the specifications of commercially available SMPD4 antibodies?

Based on available data for SMPD4 antibody product 14959-1-AP:

This antibody targets SMPD4 in ELISA applications and shows reactivity across human, mouse, and rat samples .

How does SMPD4 influence nuclear envelope dynamics during mitosis, and how can antibodies help investigate this phenomenon?

SMPD4's role in nuclear envelope dynamics presents a sophisticated research area. Knock-down of SMPD4 in human neural stem cells causes reduced proliferation rates and prolonged mitosis . More specifically, SMPD4 depletion results in abnormal nuclear envelope breakdown and reassembly during mitosis and decreased post-mitotic NPC insertion .

SMPD4 antibodies can help investigate this phenomenon through:

• Immunofluorescence microscopy to track SMPD4 localization throughout mitotic phases

• Co-immunoprecipitation studies to identify interaction partners during nuclear envelope remodeling

• Proximity ligation assays to detect in situ interactions between SMPD4 and nuclear pore complex components

• Live-cell imaging with fluorescently tagged antibodies to monitor SMPD4 dynamics during mitosis

Research suggests that in SMPD4-related disease, nuclear envelope bending (needed to insert NPCs) is impaired, which interferes with cerebral corticogenesis and pancreatic beta cell survival . This mechanism may explain both the microcephaly and diabetes phenotypes observed in patients.

What is the relationship between SMPD4, ceramide production, and primary cilia function in neural development?

Research using human induced pluripotent stem cells (iPSCs) has revealed a critical relationship between SMPD4, ceramide production, and primary cilia function. SMPD4-deficient iPSCs demonstrate shortened primary cilia, which is rescued by adding exogenous ceramide . This indicates that SMPD4's enzymatic activity producing ceramide is crucial for proper cilia formation and function.

The downstream effects are significant for neural development:

• SMPD4 knockout and patient-derived neural organoids are smaller than controls

• These organoids show a distinct loss of PAX6-positive progenitor cells

• While the number of dividing cells (pHH3-positive) remains unchanged, apoptosis is increased in patient organoids

• Neural rosettes from SMPD4-deficient cells are structurally abnormal and smaller

This evidence suggests SMPD4-mediated ceramide production is essential for proper cilia function, which in turn regulates neural progenitor survival and proliferation during brain development .

How do mouse models of SMPD4 deficiency differ from human patient phenotypes, and what implications does this have for antibody-based studies?

There are notable differences between mouse models of SMPD4 deficiency and human patient phenotypes:

These differences have significant implications for antibody-based studies:

• Species-specific antibodies may be required for certain applications

• Researchers should validate antibodies separately in human and mouse tissues

• Some phenotypes observed in patients may not be reproducible in mouse models

• Antibody-based therapeutic approaches may have different effects across species

Understanding these differences is crucial when designing experiments and interpreting results from antibody-based studies targeting SMPD4 .

What validation methods should be employed when selecting SMPD4 antibodies for specific applications?

When selecting SMPD4 antibodies, researchers should employ rigorous validation methods:

• Standard Validation:

  • Concordance with available experimental gene/protein characterization data in UniProtKB/Swiss-Prot database

  • Results in scores of "Supported," "Approved," or "Uncertain"

• Enhanced Validation:

  • Orthogonal Validation: Comparing antibody results with data from antibody-independent methods

  • Independent Antibody Validation: Comparing staining patterns from multiple antibodies targeting different epitopes of SMPD4

  • siRNA Knockdown: Evaluating decrease in antibody-based staining intensity upon SMPD4 downregulation

  • Tagged GFP Cell Lines: Assessing signal overlap between antibody staining and GFP-tagged SMPD4 protein

• Application-Specific Validation:

  • Immunocytochemistry: Validating antibody staining patterns in selected human cell lines

  • Immunohistochemistry: Assessing staining patterns in normal tissues (ideally across 44 different tissue types)

Reliability scores for immunocytochemistry applications are determined by comparing staining patterns with external evidence for protein localization, resulting in "Enhanced," "Supported," "Approved," or "Uncertain" designations .

How should researchers design experiments to study SMPD4's role in sphingolipid metabolism using antibody-based techniques?

To effectively study SMPD4's role in sphingolipid metabolism using antibody-based techniques, researchers should follow this experimental design framework:

• Subcellular Localization Studies:

  • Use immunofluorescence with validated SMPD4 antibodies to visualize protein localization to ER and nuclear envelope

  • Employ co-localization studies with markers for ER, nuclear envelope, and nuclear pore complexes

  • Confirm findings with subcellular fractionation followed by western blotting

• Enzymatic Activity Assessment:

  • Measure neutral sphingomyelinase activity in control vs. SMPD4-depleted conditions

  • Compare results from patient-derived fibroblasts showing deficient SMPD4-specific neutral sphingomyelinase activity

  • Note that (sub)cellular lipidome fractions may not change, suggesting a local function of SMPD4 on the nuclear envelope

• Protein-Protein Interaction Analysis:

  • Perform immunoprecipitation with SMPD4 antibodies followed by mass spectrometry

  • This approach has previously revealed interactions with several nuclear pore complex proteins

  • Validate key interactions with reverse co-immunoprecipitation

• Functional Studies in Disease Models:

  • Establish SMPD4 knockout/knockdown in relevant cell types (neural stem cells, fibroblasts)

  • Assess nuclear envelope dynamics during mitosis using live-cell imaging

  • Evaluate post-mitotic NPC insertion using immunofluorescence for NPC markers

  • Measure cell proliferation rates and mitotic progression

• Rescue Experiments:

  • Perform complementation with wild-type SMPD4 or mutant variants

  • Add exogenous ceramide to determine if phenotypes can be rescued (as shown in primary cilia studies)

This comprehensive approach allows for thorough investigation of SMPD4's role in sphingolipid metabolism while leveraging antibody-based techniques at multiple experimental stages.

What controls are essential when using SMPD4 antibodies for studying neurodevelopmental disorders?

When using SMPD4 antibodies to study neurodevelopmental disorders, several essential controls must be incorporated:

• Negative Controls:

  • SMPD4 knockout/knockdown samples to confirm antibody specificity

  • Secondary antibody-only controls to assess background signal

  • Isotype controls to identify non-specific binding

  • Pre-absorption controls using the immunizing peptide

• Positive Controls:

  • Tissues/cells known to express high levels of SMPD4 (e.g., developing forebrain, particularly in the ventricular zone and cerebellum)

  • Overexpression systems with tagged SMPD4 constructs

• Biological Validation Controls:

  • Patient-derived cells with confirmed SMPD4 mutations versus controls

  • Genetically modified mouse models (e.g., Smpd4 null mouse) alongside wild-type counterparts

  • Neural progenitors derived from control and patient iPSCs

• Experimental System Controls:

  • Multiple cell types to account for tissue-specific variations in SMPD4 expression

  • Developmental time course to capture dynamic expression patterns (SMPD4 is highly expressed in developing forebrain from E12.5)

  • Cross-species validation (human, mouse, rat) to identify conserved mechanisms

• Technical Controls:

  • Multiple independent SMPD4 antibodies targeting different epitopes

  • Different detection methods (western blot, immunofluorescence, ELISA)

  • Quantitative analysis with appropriate statistical methods

These controls ensure reliable, reproducible results when investigating SMPD4's role in neurodevelopmental disorders, particularly those involving microcephaly and cerebellar hypoplasia .

How can researchers address common issues with SMPD4 antibody specificity in developmental neurobiology studies?

Researchers can address SMPD4 antibody specificity issues in developmental neurobiology through these approaches:

• Validation in Knockout Systems:

  • Test antibodies in SMPD4 knockout/knockdown models to confirm absence of signal

  • Use patient-derived cells with confirmed SMPD4 mutations showing 80% reduced expression

  • Compare staining patterns in Smpd4 null mouse tissues versus wild-type controls

• Epitope Analysis:

  • Select antibodies targeting conserved regions of SMPD4 across species

  • Consider the location of known pathogenic variants which are spread over the entire protein structure

  • Avoid antibodies targeting regions affected by common variants or splice variations

• Cross-Reactivity Assessment:

  • Test for potential cross-reactivity with other sphingomyelinase family members (especially SMPD3, which may have functional redundancy with SMPD4)

  • Perform western blots to confirm detection of the expected 93 kDa protein

  • Use bioinformatic tools to predict potential cross-reactive proteins

• Optimization Strategies:

  • Adjust fixation methods for different developmental stages (formaldehyde may mask epitopes)

  • Implement antigen retrieval techniques specifically optimized for brain tissue

  • Titrate antibody concentrations for developmental tissues, which may require different conditions than adult tissues

• Alternative Approaches:

  • Complement antibody staining with in situ hybridization for SMPD4 mRNA

  • Use tagged SMPD4 constructs for localization studies

  • Employ proximity ligation assays to verify protein interactions

By implementing these strategies, researchers can enhance SMPD4 antibody specificity in developmental neurobiology studies, particularly when investigating its role in neural progenitor proliferation and cerebellar development .

What factors influence the detection of SMPD4 in different subcellular compartments, and how can antibody-based techniques be optimized for each?

SMPD4 localizes to multiple subcellular compartments, primarily the endoplasmic reticulum and nuclear envelope membranes . Several factors influence its detection across these compartments:

• Membrane Permeabilization:

  • Nuclear envelope localization requires gentle permeabilization methods

  • Stronger detergents may disrupt membrane-associated SMPD4

  • Optimization: Test gradient permeabilization protocols with Triton X-100 (0.1-0.5%) or digitonin (25-50 μg/ml)

• Fixation Methods:

  • Paraformaldehyde may cross-link membrane proteins, masking epitopes

  • Methanol fixation may better preserve SMPD4 epitopes but disrupts membrane structures

  • Optimization: Compare paraformaldehyde (2-4%) versus methanol fixation, or try methanol-acetone mixtures

• Cell Cycle Stage:

  • SMPD4 localization changes during mitosis, affecting nuclear envelope detection

  • Optimization: Synchronize cells or use cell cycle markers (e.g., pHH3) for co-labeling

• Protein Interactions:

  • SMPD4 interacts with nuclear pore complexes, potentially masking antibody binding sites

  • Optimization: Try epitope retrieval methods or antibodies targeting different SMPD4 domains

• Subcellular Compartment-Specific Approaches:

  • Nuclear Envelope: Co-stain with lamin proteins; employ super-resolution microscopy

  • Endoplasmic Reticulum: Use ER markers (calnexin, PDI); implement expansion microscopy for better resolution

  • Golgi/Secretory Pathway: Examine possible overlap with SMPD3, which functions in Golgi secretory pathways

• Tissue/Cell-Specific Variations:

  • SMPD4 expression varies across development and cell types

  • Optimization: Adjust antibody concentration and incubation times for different tissues/cell types

By addressing these factors, researchers can optimize detection of SMPD4 across subcellular compartments, improving studies of its role in nuclear envelope dynamics and sphingolipid metabolism .

How should researchers interpret conflicting results between antibody-based SMPD4 detection and functional assays in disease models?

When faced with conflicting results between antibody-based SMPD4 detection and functional assays in disease models, researchers should implement a systematic approach to interpretation:

• Evaluate Antibody Reliability:

  • Review validation scores (Enhanced, Supported, Approved, or Uncertain)

  • Verify if the antibody has undergone orthogonal or independent antibody validation

  • Reassess specificity using SMPD4 knockout controls or siRNA knockdown validation

• Consider Post-Translational Modifications:

  • Determine if antibodies detect specific modified forms of SMPD4

  • Functional activity may depend on modifications not recognized by all antibodies

  • Use antibodies targeting different epitopes to compare detection patterns

• Assess Protein vs. Activity Discrepancies:

  • Patient fibroblasts show deficient SMPD4-specific neutral sphingomyelinase activity without changes in (sub)cellular lipidome fractions

  • This suggests a local function that may not correspond with global protein levels

  • Measure enzyme activity directly using sphingomyelinase assays

• Analyze Model-Specific Differences:

  • Mouse models show cerebellar hypoplasia but not the microcephaly seen in human patients

  • Human iPSC models show neural progenitor cell death and decreased proliferation

  • Species-specific differences may explain conflicting results

• Evaluate Compensatory Mechanisms:

  • Consider functional redundancy with other sphingomyelinases like SMPD3

  • Assess whether knockout models trigger compensatory upregulation of related pathways

  • Look for adaptive changes in lipid metabolism that may mask phenotypes

• Reconciliation Strategy:

  • Combine multiple methodologies (genetic, biochemical, imaging)

  • Perform rescue experiments with wild-type SMPD4 or exogenous ceramide addition

  • Use temporal analysis to identify transient effects that might be missed in endpoint assays

By systematically evaluating these factors, researchers can better interpret conflicting results and develop a more accurate understanding of SMPD4's role in disease pathogenesis .

How might SMPD4 antibodies be utilized to investigate the link between microcephaly and insulin-dependent diabetes in patients with SMPD4 mutations?

SMPD4 antibodies offer valuable tools for investigating the unexpected link between microcephaly and insulin-dependent diabetes in patients with SMPD4 mutations:

• Comparative Tissue Analysis:

  • Perform immunohistochemistry on pancreatic and neural tissues from animal models

  • Compare SMPD4 localization patterns between pancreatic beta cells and neural progenitors

  • Investigate potential similarities in subcellular phenotypes that might explain shared vulnerability

• Mechanistic Investigation:

  • Use co-immunoprecipitation with SMPD4 antibodies to identify tissue-specific interaction partners

  • Compare nuclear envelope dynamics in beta cells versus neural progenitors

  • Examine whether both cell types show similar defects in nuclear pore complex insertion

• Developmental Timeline Studies:

  • Track SMPD4 expression during pancreatic development using immunohistochemistry

  • Compare with known developmental timeline in brain (high expression in developing forebrain from E12.5)

  • Determine if critical developmental windows overlap for both tissues

• Cellular Stress Response:

  • Investigate whether both cell types show similar apoptotic responses to SMPD4 deficiency

  • Fibroblasts from affected individuals are more susceptible to apoptosis under stress conditions

  • Use SMPD4 antibodies to monitor protein levels during stress responses

• Ceramide Signaling Pathway Analysis:

  • Study ceramide production and distribution in both neural and pancreatic tissues

  • Examine if exogenous ceramide can rescue phenotypes in both cell types (similar to cilia rescue)

  • Map ceramide-responsive signaling pathways in both tissues using phospho-specific antibodies

This research direction could provide crucial insights into why these seemingly unrelated phenotypes co-occur, potentially revealing shared cellular mechanisms and identifying therapeutic targets for both conditions .

What role might SMPD4 play in primary cilia function, and how can antibody-based techniques help elucidate this connection?

Recent research has revealed a critical connection between SMPD4 and primary cilia function that can be further explored using antibody-based techniques:

• Structural Analysis of Cilia:

  • Use immunofluorescence with SMPD4 antibodies alongside cilia markers (acetylated tubulin, ARL13B)

  • Human iPSCs lacking SMPD4 exhibit shortened primary cilia, which can be rescued by adding exogenous ceramide

  • Quantify cilia length, frequency, and morphology in control versus SMPD4-deficient conditions

• SMPD4 Localization at Ciliary Base:

  • Implement super-resolution microscopy to precisely map SMPD4 distribution relative to basal bodies and transition zones

  • Compare SMPD4 localization before and during ciliogenesis

  • Look for potential co-localization with ciliary vesicle transport machinery

• Ceramide Distribution in Ciliary Membrane:

  • Use both SMPD4 antibodies and ceramide-specific probes/antibodies

  • Examine whether ceramide enrichment occurs at specific ciliary domains

  • Determine if SMPD4 deficiency alters ceramide distribution within the ciliary membrane

• Ciliary Signaling Pathway Analysis:

  • Investigate how SMPD4 deficiency affects key ciliary signaling pathways (Hedgehog, Wnt)

  • These pathways are crucial for neural development and cerebellar formation

  • Use antibodies against downstream effectors to monitor pathway activity

• Dynamic Studies During Development:

  • Track SMPD4 and cilia development in cerebellar Purkinje cells

  • Mouse models show cerebellar hypoplasia due to failure of Purkinje cell development

  • Analyze temporal relationships between SMPD4 expression, cilia formation, and Purkinje cell differentiation

• Rescue Experiments:

  • Compare cilia structure and function after:

    • Wild-type SMPD4 reintroduction

    • Mutant SMPD4 expression

    • Exogenous ceramide addition

  • Quantify rescue effects on neural progenitor proliferation and survival

This research would establish the mechanistic link between SMPD4-mediated sphingolipid metabolism and primary cilia function, potentially explaining how SMPD4 mutations lead to neurodevelopmental disorders through disruption of cilia-dependent signaling .

How might SMPD4 antibodies contribute to developing therapeutic approaches for SMPD4-related disorders?

SMPD4 antibodies could play pivotal roles in developing therapeutic approaches for SMPD4-related disorders through several avenues:

• Target Validation and Disease Modeling:

  • Use antibodies to screen patient-derived cells for SMPD4 expression levels

  • Quantitative assessment showed 80% reduced SMPD4 expression in patient fibroblasts

  • Monitor disease progression in animal models through tissue-specific expression analysis

  • Validate therapeutic targets in the sphingolipid metabolism pathway

• Phenotypic Screening Platforms:

  • Develop high-content screening assays using SMPD4 antibodies to detect:

    • Nuclear envelope abnormalities

    • NPC insertion defects

    • Primary cilia formation

    • Neural progenitor survival

  • Screen compound libraries for molecules that rescue these phenotypes

• Biomarker Development:

  • Identify disease-specific post-translational modifications of SMPD4

  • Develop modified-specific antibodies as potential diagnostic tools

  • Monitor treatment efficacy using antibody-based detection of downstream pathways

• Therapeutic Modality Assessment:

  • Evaluate ceramide replacement therapy effectiveness

    • Human iPSCs lacking SMPD4 show shortened primary cilia that are rescued by exogenous ceramide

  • Monitor ceramide levels and distribution after treatment

  • Assess restoration of neural progenitor proliferation and reduced apoptosis

• Gene Therapy Monitoring:

  • Use antibodies to track expression of delivered wild-type SMPD4

  • Quantify restoration of protein levels in target tissues

  • Correlate protein expression with functional recovery

• Cell-Based Therapy Optimization:

  • Develop protocols for neural progenitor differentiation from patient iPSCs

  • Monitor SMPD4 expression during differentiation

  • Assess therapeutic potential of corrected progenitor cells

• Precision Medicine Approach:

  • Create antibodies specific to common SMPD4 mutations

  • Nineteen distinct pathogenic variants in SMPD4 have been described

  • Enable variant-specific approaches based on molecular phenotyping

These approaches could lead to desperately needed therapies for patients with SMPD4-related disorders, potentially addressing both neurological symptoms and insulin-dependent diabetes that develops in those surviving beyond infancy .